SCI Pharmtech, Inc. (TPE:4119)

Market Cap	6.21B -38.1%
Revenue (ttm)	1.39B -1.6%
Net Income	115.35M -76.2%
EPS	0.96 -76.4%
Shares Out	119.51M
PE Ratio	54.09
Forward PE	n/a
Dividend	1.50 (2.88%)
Ex-Dividend Date	Jul 1, 2025

Volume	138,994
Average Volume	151,659
Open	53.30
Previous Close	53.10
Day's Range	51.90 - 53.30
52-Week Range	46.85 - 88.60
Beta	0.12
RSI	50.36
Earnings Date	Mar 18, 2026

About SCI Pharmtech

SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychloroquine sulfate, loxoprofen sodium, methylphenidate HCl, pentobarbital sodium, pimobendan, probucol, propafenone HCI, sodium valproate, thiopental, an...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1987
• Employees: 239
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 4119

Financial Performance

In 2024, SCI Pharmtech's revenue was 1.52 billion, an increase of 26.54% compared to the previous year's 1.20 billion. Earnings were 534.68 million, an increase of 81.42%.